CY1122385T1 - Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β - Google Patents

Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β

Info

Publication number
CY1122385T1
CY1122385T1 CY20191101067T CY191101067T CY1122385T1 CY 1122385 T1 CY1122385 T1 CY 1122385T1 CY 20191101067 T CY20191101067 T CY 20191101067T CY 191101067 T CY191101067 T CY 191101067T CY 1122385 T1 CY1122385 T1 CY 1122385T1
Authority
CY
Cyprus
Prior art keywords
tumor
selective
modified
adeno
mutants
Prior art date
Application number
CY20191101067T
Other languages
Greek (el)
English (en)
Inventor
Tony Reid
Farah Hedjran
Shantanu Kumar
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of CY1122385T1 publication Critical patent/CY1122385T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CY20191101067T 2009-03-02 2019-10-10 Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β CY1122385T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15682209P 2009-03-02 2009-03-02
EP10749205.0A EP2403951B1 (en) 2009-03-02 2010-03-02 Tumor-selective adenovirus e1a and e1b mutants
PCT/US2010/025926 WO2010101921A2 (en) 2009-03-02 2010-03-02 Tumor-selective e1a and e1b mutants

Publications (1)

Publication Number Publication Date
CY1122385T1 true CY1122385T1 (el) 2021-01-27

Family

ID=42710189

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101067T CY1122385T1 (el) 2009-03-02 2019-10-10 Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β

Country Status (15)

Country Link
US (6) US9073980B2 (enExample)
EP (4) EP4123030A1 (enExample)
JP (5) JP6072414B2 (enExample)
KR (4) KR102020018B1 (enExample)
CY (1) CY1122385T1 (enExample)
DK (2) DK3029144T3 (enExample)
ES (2) ES2557812T3 (enExample)
HR (2) HRP20151396T1 (enExample)
HU (2) HUE046565T2 (enExample)
LT (1) LT3029144T (enExample)
PL (2) PL2403951T3 (enExample)
PT (2) PT2403951E (enExample)
SI (2) SI3029144T1 (enExample)
SM (2) SMT201900565T1 (enExample)
WO (1) WO2010101921A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046565T2 (hu) 2009-03-02 2020-03-30 Univ California Tumorszelektív adenovírus E1A és E1B mutánsok
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
EP3022320B2 (en) 2013-07-19 2024-09-25 Ludwig Institute for Cancer Research Ltd Whole-genome and targeted haplotype reconstruction
PL3198009T3 (pl) 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
AU2017336546C1 (en) * 2016-09-27 2025-05-29 Epicentrx, Inc. Immunomodulatory fusion proteins
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
US20190352616A1 (en) * 2017-01-30 2019-11-21 Epicentrx, Inc. Multiple transgene recombinant adenovirus
MX2019008922A (es) * 2017-01-30 2020-01-20 Epicentrx Inc Mutantes de la caja tata y de la caja caat selectivas de tumor.
CA3059605A1 (en) 2017-04-10 2018-10-18 Epicentrx, Inc. Method for producing recombinant virus
EA201990822A1 (ru) * 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
CA3064892A1 (en) * 2017-05-24 2018-11-29 Epicentrx, Inc. Anti-angiogenic adenovirus
KR102702230B1 (ko) * 2017-05-26 2024-09-03 에피센트알엑스, 인코포레이티드 트랜스진을 보유하는 재조합 아데노바이러스
KR102757384B1 (ko) 2017-09-27 2025-01-20 에피센트알엑스, 인코포레이티드 면역조절 융합 단백질
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
US12295976B2 (en) 2018-03-28 2025-05-13 Epicentrx, Inc. Personalized cancer vaccines
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
US12233096B2 (en) * 2018-08-31 2025-02-25 Orca Therapeutics B.V. Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells
JP7640538B2 (ja) 2019-10-08 2025-03-05 トラスティーズ オブ ボストン カレッジ 複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
CN114262691A (zh) * 2020-09-16 2022-04-01 杭州康万达医药科技有限公司 分离的能够用于表达外源基因的溶瘤腺病毒、载体、治疗剂及其用途
WO2024015876A1 (en) 2022-07-13 2024-01-18 Epicentrx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof
CN118931897B (zh) * 2024-06-27 2026-01-16 中山大学 一种识别肿瘤细胞并诱导其焦亡的基因、重组载体和重组病毒及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5352775A (en) 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
EP0659209A1 (en) 1991-07-26 1995-06-28 The University Of Rochester Cancer therapy utilizing malignant cells
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
EP0711829A3 (en) * 1993-09-15 1997-07-09 Viagene Inc Recombinant alphavirus vector
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US5902925A (en) 1996-07-01 1999-05-11 Integrated Sensor Solutions System and method for high accuracy calibration of a sensor for offset and sensitivity variation with temperature
GB9626029D0 (en) 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
US20050287120A1 (en) 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
EP1135514B1 (en) * 1999-01-28 2009-05-13 Onyx Pharmaceuticals, Inc. E1b-deleted adenoviral shuttle vectors
AU2001257611A1 (en) * 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
AU2001285263A1 (en) * 2000-08-25 2002-03-13 The General Hospital Corporation Selective precipitation of viruses
CN1183250C (zh) 2000-12-01 2005-01-05 卫健生物科技有限公司 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法
GB0117198D0 (en) 2001-07-13 2001-09-05 Btg Int Ltd Anti-neoplastic viral agents
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
EP1585964A4 (en) * 2002-08-28 2008-07-16 Introgen Therapeutics Inc CHROMATOGRAPHIC METHODS FOR PURIFYING ADENOVIRUSES
CA2590257A1 (en) * 2003-11-14 2005-06-09 Per Sonne Holm Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
WO2006070024A2 (de) * 2004-12-31 2006-07-06 Per Sonne Holm E1 -minus adenoviren und deren verwendung
CN101663397B (zh) 2007-04-20 2015-04-22 宝生物工程株式会社 用于基因治疗的载体
HUE046565T2 (hu) 2009-03-02 2020-03-30 Univ California Tumorszelektív adenovírus E1A és E1B mutánsok

Also Published As

Publication number Publication date
KR20110122866A (ko) 2011-11-11
US20250327037A1 (en) 2025-10-23
SI2403951T1 (sl) 2016-04-29
JP2012519014A (ja) 2012-08-23
EP2403951A4 (en) 2012-08-22
JP2018113971A (ja) 2018-07-26
SI3029144T1 (sl) 2019-11-29
PT3029144T (pt) 2019-10-28
WO2010101921A3 (en) 2011-01-06
DK2403951T3 (en) 2016-01-11
US11618888B2 (en) 2023-04-04
US20160017294A1 (en) 2016-01-21
US20110318311A1 (en) 2011-12-29
US20190136204A1 (en) 2019-05-09
KR20190104643A (ko) 2019-09-10
JP6375273B2 (ja) 2018-08-15
US9073980B2 (en) 2015-07-07
US20210171917A1 (en) 2021-06-10
SMT201500329B (it) 2016-02-25
WO2010101921A2 (en) 2010-09-10
ES2750305T3 (es) 2020-03-25
PL3029144T3 (pl) 2020-06-01
KR20180049188A (ko) 2018-05-10
US10876097B2 (en) 2020-12-29
KR20170077278A (ko) 2017-07-05
HUE026386T2 (en) 2016-06-28
EP3029144A1 (en) 2016-06-08
HRP20191808T1 (hr) 2019-12-27
US20230272349A1 (en) 2023-08-31
JP2020078326A (ja) 2020-05-28
KR101922539B1 (ko) 2018-11-27
JP2022023074A (ja) 2022-02-07
EP2403951B1 (en) 2015-09-30
JP7326396B2 (ja) 2023-08-15
JP6817979B2 (ja) 2021-01-20
PT2403951E (pt) 2016-01-29
SMT201900565T1 (it) 2019-11-13
EP3029144B1 (en) 2019-07-10
JP2016028035A (ja) 2016-02-25
KR102150027B1 (ko) 2020-10-26
DK3029144T3 (da) 2019-10-21
EP4123030A1 (en) 2023-01-25
LT3029144T (lt) 2019-10-25
EP3591059B1 (en) 2022-07-20
PL2403951T3 (pl) 2016-04-29
EP3591059A1 (en) 2020-01-08
HRP20151396T1 (hr) 2016-03-25
HUE046565T2 (hu) 2020-03-30
US12195766B2 (en) 2025-01-14
JP6072414B2 (ja) 2017-02-01
EP2403951A2 (en) 2012-01-11
KR102020018B1 (ko) 2019-09-09
ES2557812T3 (es) 2016-01-28
KR101752910B1 (ko) 2017-06-30

Similar Documents

Publication Publication Date Title
WO2010101921A3 (en) Tumor-selective e1a and e1b mutants
CY1125475T1 (el) Χρηση οξυγονωμενης θειικης χοληστερολης (ocs) για την αντιμετωπιση της νεφρικης δυσλειτουργιας
MX2012002163A (es) Agentes novedosos y usos de los mismos.
IL268554A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
CL2016001507A1 (es) Compuestos para tratar pacientes con células cancerosas mutantes ros1
BRPI0809663A2 (pt) Composição de vírus vivo atenuado, método de diminuição da inativação de composição de vírus vivo atenuado e kit respectivo
BR112019024813A2 (pt) adenovírus recombinantes portando transgenes
EP2558478A4 (en) AT 5 POSITIONS MODIFIED PYRIMIDINES AND THEIR USE
EP2214495A4 (en) NATURALLY PHOTODYNAMIC ACTIVE SUBSTANCES AND ITS USE
BR112012016203A2 (pt) "métodos para melhoria da proliferaçõ e atividade das células exterminadoras naturais"
MX2015006973A (es) Inmunoterapia con agentes de enlace.
MY183703A (en) Oncolytic adenovirus encoding a b7 protein
EP2118123A4 (en) STABILIZED P53 PEPTIDES AND ITS USES
CY1110002T1 (el) Τροποποιημενη πρωτεϊνη ηεχον αδενοϊου και χρησεις αυτης
BR112015032690A2 (pt) uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases
DK2068909T3 (da) Modificerede FGF-21-polypeptider og anvendelse heraf
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
IL240895A0 (en) Tri-aryl compounds and compositions comprising the same
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
NZ600974A (en) Binding members for human cytomegalovirus
WO2017062511A8 (en) Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
BR112012010824A2 (pt) adenovirus simios e métodos de uso
PH12012500740A1 (en) Nutritional compositions including a high protein component and exogenous nucleotides